Full-Time

Safety Scientist

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS cancers

Compensation Overview

$116k - $145k/yr

Junior, Mid

San Carlos, CA, USA

This position is hybrid, requiring some in-office days.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Requirements
  • A relevant postgraduate qualification (e.g., MD, PharmD, PHD/MSc in a Life sciences discipline, or other post-graduate health professional qualifications)
  • 1 or more years of drug development experience in the pharmaceutical or related industry
  • Detail-oriented with ability prioritize tasks and function independently as appropriate
  • Strong learning orientation, curiosity, and commitment to science and patients
  • Excellent written and verbal communication skills.
Responsibilities
  • Proactive medical safety surveillance of ongoing clinical trials for identification of safety
  • Conduct ongoing safety data reviews; prepare and present summaries to internal stakeholders.
  • Medical review of individual case safety reports, routine review of safety data and pertinent scientific literature articles.
  • Identify potential clinical safety issues for ongoing clinical trials based on emerging safety data.
  • May perform safety reviews of relevant sections of clinical trial protocols, Investigator’s Brochures (including reference safety information), clinical study reports, informed consent forms, DSURs, and other study related documents, as required.
  • Supports authoring or otherwise contributes to the preparation of aggregate safety reports and risk management plans (RMPs).
  • Conducts signal detection and evaluation activities for assigned products in collaboration with senior Safety Science team member(s) as part of the continuous benefit-risk evaluation throughout the product lifecycle.
  • Establish and maintain collaborative working relationships with all key stakeholders (e.g., clinical study teams, study sites, CROs).
  • Consistently comply with all governing laws, regulations, RevMed standard operating procedures (SOPs) and other guidelines.
Desired Qualifications
  • Understanding of the scientific aspects of safety, PV (including GVP, GCP), and clinical/patient risk management ​
  • Exposure to Safety Operations and experience with individual case review
  • Knowledge and/or experience with clinical trial management and data review

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a unique Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

11%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.